Lucid Genomics Announce Co-Marketing Partnership with QIAGEN to Advance Long-Read and Dark Genome Interpretation
The Collaboration brings AI-driven, long-read native genomic interpretation to QIAGEN's global customer base across research and clinical genomics.
BERLIN, Germany, April 29, 2026 — Lucid Genomics, the long-read native genomic interpretation platform, today announced a co-marketing partnership with QIAGEN to make AI-driven long-read genomic interpretation more accessible to researchers and clinical laboratories worldwide.
Under the agreement, QIAGEN customers gain a clear path to long-read native interpretation through the Lucid Interpretation Platform - while Lucid customers benefit from access to QIAGEN's industry-leading genomics portfolio.
A natural fit across the genomics workflow
“QIAGEN is one of the most trusted names in genomics — their products are in labs everywhere from discovery research to clinical diagnostics,” said Achim Geppert, Chief Commercial Officer at Lucid Genomics. “Partnering with them means our long-read native interpretation platform reaches the customers who need it most, through workflows and channels they already rely on. It’s a natural fit, and a meaningful step in building the interpretation layer the long-read transition demands.”
Closing the long-read interpretation gap
Long-read sequencing is rapidly becoming the standard for comprehensive genomic analysis, unlocking variant classes that short-read technologies cannot reliably resolve — including structural variants, tandem repeats, methylation, and complex regions of the genome. But interpretation tooling has lagged behind the data, leaving labs with capable instruments and limited downstream analysis options.
Lucid Genomics was built as a long-read native from the ground up. Its AI-driven platform translates the full information content of PacBio and Oxford Nanopore data into clinically and scientifically actionable results.A natural fit across the genomics workflow
About Lucid Genomics
Lucid Genomics is a bioinformatics company dedicated to making genomic data analysis faster, more accurate, and more accessible. The company’s cloud-native platform supports secondary and tertiary analysis for clinical laboratories, research institutions, and biotechnology companies working with next-generation and long-read sequencing technologies.
Media Contact
Lucid Genomics Communications